Streetbeat News

Price Targets

CCK

JP Morgan analyst Jeffrey Zekauskas has maintained a Neutral rating on Crown Holdings (NYSE:CCK) and raised the price target from $88 to $93.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:35 pm

CRMD

RBC Capital Markets has initiated coverage on CorMedix Inc (CRMD) with an Outperform rating and a price target of $6. The company's antimicrobial asset, DefenCath, has the potential to capture an attractive hemodialysis market. Despite previous CRLs, DefenCath's data remains robust. The analyst, Gregory Renza, is impressed with CRMD's robust launch and reimbursement plans, aiming for a peak potential of $600 million in the U.S. by the 2030s. The analyst believes that DefenCath's resubmission is more likely than not to be approved.

Portfolio Pulse from Vandana Singh

August 10, 2023 | 4:35 pm

CRL

JP Morgan analyst Tycho Peterson has maintained an Overweight rating on Charles River (NYSE:CRL) and raised the price target from $225 to $250.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:34 pm

BSAC

JP Morgan analyst Domingos Falavina maintains a Neutral rating on Banco Santander Chile (NYSE:BSAC) and raises the price target from $19 to $21.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:33 pm

ATMU

JP Morgan analyst Tami Zakaria maintains an Overweight rating on Atmus Filtration Techs (NYSE:ATMU) and raises the price target from $28 to $29.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:32 pm

ARCO

JP Morgan analyst Ian Luketic maintains an Overweight rating on Arcos Dorados Holdings (NYSE:ARCO) and raises the price target from $10 to $13.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:31 pm

ALKT

Citigroup analyst Andrew Schmidt maintains a Buy rating on Alkami Technology (NASDAQ:ALKT) and raises the price target from $19 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:26 pm

BCSF

Citigroup analyst Arren Cyganovich has maintained a Neutral rating on Bain Capital Specialty (NYSE:BCSF) and raised the price target from $12 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:25 pm

BXP

Citigroup analyst Emmanuel Korchman has maintained a Neutral rating on Boston Properties (NYSE:BXP) and raised the price target from $54 to $66.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:23 pm

BLND

Blend Labs reported better-than-expected Q2 financial results and issued Q3 consolidated revenue guidance. Wells Fargo raised its price target on Blend Labs' stock from $1 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:22 pm